MedTrace Logo

Consolidation PET-based and Donor-based After Salvage Therapy in Patients With HL in Relapse or Refractory

NCT00879528 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 264

Last updated 2016-08-17

No results posted yet for this study

Summary

PET-based consolidation and donor-based therapy after rescue in patients with Hodgkin's lymphoma refractory at first line therapy, or relapse early or late, undergone a second line chemotherapy.

Conditions

  • Hodgkin's Lymphoma

Interventions

OTHER

Patients with negative PET after salvage therapy

All patients included in the study will treat with a salvage scheme according to each center. After the end of salvage therapy, consolidation depends on the outcome of PET: PET negative: These patients will follow a standard treatment that includes high-dose chemotherapy with reinfusion of autologous peripheral stem cells.

OTHER

Patients with positive PET after salvage therapy

All patients included in the study will treat with a salvage scheme according to each center. After the end of salvage therapy, consolidation depends on the outcome of PET PET positive, the consolidation therapy consists of 2 phases: * phase1:common to all consists in a series of high-dose chemotherapy with Melphalan 200 mg/sqm, followed by reinfusion of autologous peripheral stem cells * phase2:depends on the availability of a compatible donor. If there is a donor, the patient will continue with an allogeneic transplant preceded by a reduced intensity conditioning. If there is not a donor, the patient will continue with a second round of high-dose chemotherapy with BEAM with reinfusion of autologous peripheral stem cells.

Sponsors & Collaborators

  • Istituto Clinico Humanitas

    collaborator OTHER

  • Fondazione Italiana Linfomi - ETS

    lead OTHER

Principal Investigators

  • Luca Castagna, MD · Istituto Clinico Humanitas, Dipartimento di Oncologia e Ematologia

  • Armando Santoro, MD · Istituto Clinico Humanitas, Dipartimento di Oncologia e Ematologia

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2010-05-31
Completion
2015-09-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00879528 on ClinicalTrials.gov